Press Releases
Date picker
Category
Results per page
Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system
Kancera AB (Nasdaq First North Growth Market: KAN) reports results from an in-depth immunological analysis of blood samples from healthy subjects in the ongoing Phase Ib program. The analysis shows…
Interim report for the third quarter 2019, 1 January – 30 September 2019
Third quarter in brief 1 July – 30 September 2019 Net sales for the period (January to September) amounted to SEK 3,3 Million (0,1 Million) of which the third quarter…
Kancera and partner revise the patent strategy for the HDAC project
This is a translation of a press release in Swedish published in Stockholm 2019-11-22 Kancera AB (Nasdaq First North Growth Market: KAN) and Grünenthal work together to develop HDAC inhibitors…
Kancera updates the clinical development plan for KAND567
This is a translation of a press release in Swedish published 2019-11-21 Kancera AB (Nasdaq First North Growth Market: KAN) today announces that the company intends to complete the final…
Kancera unveils preclinical findings for its lead compound, KAND567, at world’s largest cardiovascular conference
Kancera AB (Nasdaq First North: KAN) announces the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to…
Kancera develops the dosing strategy for KAND567 which means an added delay of the phase 1b study
Kancera today announces that a further developed dosing strategy is intended to be tested for the treatment with KAND567. The reason is that the modified intravenous dosing studied in the…
Interim report for the second quarter 2019, 1 January – 30 June 2019
Regulatory
Second quarter in brief1 April – 30 June 2019 Net sales for the period (January to June) amounted to SEK 3,1 Million (0 Million) of which the second quarter contributed…
Kancera provides an operational update and announces an issue of shares in accordance with the agreement with Global Corporate Finance
Kancera AB (Nasdaq First North: KAN) announces that the company's clinical Phase Ib study according to plan will start again today. The aim is to report the study in November…
Kancera completes the third and final installment for the Fractalkine project
Kancera today announces that the third installment for the Fractalkine project and KAND567 is carried out according to the acquisition agreement. The payment that was activated in connection with the…
Kancera provides operational update and announces issue of shares according to agreement with Global Corporate Finance
Kancera AB (Nasdaq First North: CAN) today announced that two patent applications within the fractalkine project are now entering international phase and that the agreement with US Global Corporate Finance…